In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

SALT LAKE CITY - LifeVantage Corporation (NASDAQ:LFVN), a $271 million market cap player in the health and wellness sector with impressive 79% gross profit margins, today announced the successful ...

American host and television producer Oprah Winfrey recently shared her initial experience of taking the weight loss drug GLP ...

GLP-1 drugs mimic a hormone that sends the brain signals of fullness. Researchers theorize that the drugs could work the same ...

Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025 ...

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

An hour of moderate-intensity exercise reduced sensations of hunger in people with overweight and obesity in a recent study.

LifeVantage (LFVN) announced the completion of an international in vitro cell study that investigated the effects of its international ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of cardiovascular disease.